William Harris Net Worth

The estimated Net Worth of William G Harris is at least $3.3 million dollars as of 30 October 2020. Mr. Harris owns over 2,497 units of Soleno Therapeutics Inc stock worth over $3,219,445 and over the last 7 years he sold SLNO stock worth over $4,345. In addition, he makes $75,050 as Independent Director at Soleno Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Harris SLNO stock SEC Form 4 insiders trading

William has made over 1 trades of the Soleno Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 2,497 units of SLNO stock worth $4,345 on 30 October 2020.

The largest trade he's ever made was selling 2,497 units of Soleno Therapeutics Inc stock on 30 October 2020 worth over $4,345. On average, William trades about 104 units every 0 days since 2017. As of 30 October 2020 he still owns at least 66,271 units of Soleno Therapeutics Inc stock.

You can see the complete history of Mr. Harris stock trades at the bottom of the page.

William Harris biography

William (Bill) G. Harris serves as Independent Director of the Company. Mr. Harris has been a member of our Board of Directors since June 2014. Since 2001, he has been the Senior Vice President of Finance and Chief Financial Officer of Xenoport, Inc. From 1996 to 2001, he held several positions with Coulter Pharmaceutical, Inc., a biotechnology company engaged in the development of novel therapies for the treatment of cancer and autoimmune diseases, the most recent of which was Senior Vice President and Chief Financial Officer, Corixa Corp., a developer of immunotherapeutic products, which was acquired by Coulter Pharmaceutical in 2000. Prior to Coulter Pharmaceutical, from 1990 to 1996, Mr. Harris held several positions at Gilead Sciences, Inc., the most recent of which was director of finance. Mr. Harris received a B.A. from the University of California, San Diego and an M.B.A. from Santa Clara University, Leavey School of Business and Administration.

What is the salary of William Harris?

As the Independent Director of Soleno Therapeutics Inc, the total compensation of William Harris at Soleno Therapeutics Inc is $75,050. There are 6 executives at Soleno Therapeutics Inc getting paid more, with Anish Bhatnagar having the highest compensation of $822,089.

How old is William Harris?

William Harris is 62, he's been the Independent Director of Soleno Therapeutics Inc since 2014. There are 2 older and 8 younger executives at Soleno Therapeutics Inc. The oldest executive at Soleno Therapeutics Inc is Ernest Mario, 81, who is the Independent Chairman of the Board.

What's William Harris's mailing address?

William's mailing address filed with the SEC is 203 REDWOOD SHORES PKWY, STE 500, , REDWOOD CITY, CA, 94065.

Insiders trading at Soleno Therapeutics Inc

Over the last 9 years, insiders at Soleno Therapeutics Inc have traded over $134,327,999 worth of Soleno Therapeutics Inc stock and bought 56,592,152 units worth $70,324,676 . The most active insiders traders include Advisors Llcperceptive Life..., Jack W Schuler et Andrew Sinclair. On average, Soleno Therapeutics Inc executives and independent directors trade stock every 29 days with the average trade being worth of $36,911,570. The most recent stock trade was executed by Kristen Yen on 28 August 2024, trading 10,705 units of SLNO stock currently worth $507,738.

What does Soleno Therapeutics Inc do?

soleno therapeutics, inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. the company is currently advancing its lead candidate, dccr, a once-daily oral tablet for the treatment of pws, into a phase iii clinical development program in early 2018.

Complete history of Mr. Harris stock trades at Soleno Therapeutics Inc

Soleno Therapeutics Inc executives and stock owners

Soleno Therapeutics Inc executives and other stock owners filed with the SEC include:

• Anish Bhatnagar,
  President, Chief Executive Officer, Director
• Dr. Anish Bhatnagar,
  Pres, CEO, COO & Director
• Patricia Hirano,
  Vice President - Regulatory Affairs
• Kristen Yen,
  Vice President - Clinical Operations
• James H. MacKaness,
  Chief Financial Officer
• Ernest Mario,
  Independent Chairman of the Board
• William Harris,
  Independent Director
• Gwen Melincoff,
  Independent Director
• Birgitte Volck,
  Independent Director
• Andrew Sinclair,
  Independent Director
• Dr. Neil M. Cowen M.B.A., Ph.D., MBA,
  Sr. VP of Drug Devel.
• Anthony Wondka,
  Sr. VP & GM
• Dawn Carter Bir,
  
• Jack W Schuler,
  
• Larry N Feinberg,
  10% owner
• Opportunity, Llc Vivo Oppor...,
  
• Jonathan Wolter,
  Chief Financial Officer
• Stephen Kirnon,
  Director
• Mahendra Shah,
  Director
• Rajen Dalal,
  Director
• Edgar Engleman,
  Director
• Ventures V, Llc Vivo,
  10% owner
• Steinar J Engelsen,
  Director
• James Walter Glasheen,
  Director
• Stuart J Collinson,
  Director
• Ventures V, Llc Vivo Ventur...,
  
• Raymond W. Urbanski,
  CHIEF DEVELOPMENT OFFICER
• Management Vii Llctechnolog...,
  
• Mangement Llcbioasia Invest...,
  
• Larry Noracle Partners Lp F...,
  
• Llp Abingworth,
  10% owner
• Ventures V, Llc Vivo Ventur...,
  
• Group Inc.Carlyle Holdings ...,
  
• Meredith Manning,
  Chief Commercial Officer
• Michael F. Huang,
  Sr. VP of Clinical Development
• Matthew Pauls,
  
• Group Inc.Carlyle Holdings ...,
  
• Advisors Llcperceptive Life...,
  
• James H Mackaness,
  CHIEF FINANCIAL OFFICER